UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, D.C. 20549
|
|
Delaware
|
|
|
|
|
|
|
|
32-0454912
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
|
|
|
|
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
800 N. Glebe Road
|
,
|
Suite 500
|
,
|
Arlington
|
,
|
Virginia
|
|
22203
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Class A Common Stock of Evolent Health, Inc., par value $0.01 per share
|
EVH
|
New York Stock Exchange
|
Item
|
|
Page
|
|
|
|
1.
|
||
2.
|
||
3.
|
||
4.
|
||
|
|
|
1.
|
||
1A.
|
||
2.
|
||
3.
|
||
4.
|
||
5.
|
||
6.
|
||
|
•
|
the significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with Passport or another significant partner, or multiple partners in the aggregate;
|
•
|
uncertainty relating to expected future revenues from and our relationship with one of our largest customers, Passport, and the value of our pending investment in Passport, including as a result of the ongoing Medicaid request for proposal process in the Commonwealth of Kentucky;
|
•
|
the structural change in the market for health care in the United States;
|
•
|
uncertainty in the health care regulatory framework, including the potential impact of policy changes;
|
•
|
uncertainty in the public exchange market;
|
•
|
the uncertain impact of CMS waivers to Medicaid rules and changes in membership and rates;
|
•
|
the uncertain impact the results of elections may have on health care laws and regulations;
|
•
|
our ability to effectively manage our growth and maintain an efficient cost structure;
|
•
|
our ability to offer new and innovative products and services;
|
•
|
risks related to completed and future acquisitions, investments, alliances and joint ventures, including the partnership with GlobalHealth, the acquisition of assets from New Mexico Health Connections (“NMHC”), and the acquisitions of Valence Health Inc., excluding Cicerone Health Solutions, Inc. (“Valence Health”), Aldera Holdings, Inc. (“Aldera”), NCIS Holdings, Inc. (“New Century Health”), and the pending transactions with Passport, which may be difficult to integrate, divert management resources, or result in unanticipated costs or dilute our stockholders;
|
•
|
our ability to consummate opportunities in our pipeline;
|
•
|
certain risks and uncertainties associated with the pending Passport transaction, the acquisition of assets from NMHC and the acquisitions of Valence Health, Aldera and New Century Health, including future revenues may be less than expected, the timing and extent of new lives expected to come onto the platform may not occur as expected and the expected results of Evolent may not be impacted as anticipated;
|
•
|
risks relating to our ability to maintain profitability for our and New Century Health’s performance-based contracts and products, including capitation and risk-bearing contracts;
|
•
|
the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners’ plans (including in Florida), premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;
|
•
|
our ability to attract new partners and successfully capture new growth opportunities;
|
•
|
the increasing number of risk-sharing arrangements we enter into with our partners;
|
•
|
our ability to recover the significant upfront costs in our partner relationships;
|
•
|
our ability to estimate the size of our target markets;
|
•
|
our ability to maintain and enhance our reputation and brand recognition;
|
•
|
consolidation in the health care industry;
|
•
|
competition which could limit our ability to maintain or expand market share within our industry;
|
•
|
risks related to governmental payer audits and actions, including whistleblower claims;
|
•
|
our ability to partner with providers due to exclusivity provisions in our contracts;
|
•
|
restrictions and penalties as a result of privacy and data protection laws;
|
•
|
adequate protection of our intellectual property, including trademarks;
|
•
|
any alleged infringement, misappropriation or violation of third-party proprietary rights;
|
•
|
our use of “open source” software;
|
•
|
our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;
|
•
|
our reliance on third parties and licensed technologies;
|
•
|
our ability to use, disclose, de-identify or license data and to integrate third-party technologies;
|
•
|
data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;
|
•
|
online security risks and breaches or failures of our security measures, including with respect to privacy of health information;
|
•
|
our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our users;
|
•
|
our reliance on third-party vendors to host and maintain our technology platform;
|
•
|
our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;
|
•
|
the risk of a significant reduction in the enrollment in our health plan;
|
•
|
our ability to accurately underwrite performance-based risk-bearing contracts;
|
•
|
risks related to our offshore operations;
|
•
|
our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;
|
•
|
the risk of potential future goodwill and intangible asset impairment on our results of operations;
|
•
|
our indebtedness and our ability to obtain additional financing;
|
•
|
our ability to achieve profitability in the future;
|
•
|
the requirements of being a public company;
|
•
|
our adjusted results may not be representative of our future performance;
|
•
|
the risk of potential future litigation;
|
•
|
the impact of changes in accounting principles and guidance on our reported results;
|
•
|
our holding company structure and dependence on distributions from Evolent Health LLC;
|
•
|
our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;
|
•
|
our ability to utilize benefits under the tax receivables agreement described herein;
|
•
|
our ability to realize all or a portion of the tax benefits that we currently expect to result from past and future exchanges of Class B common units of Evolent Health LLC for our Class A common stock, and to utilize certain tax attributes of Evolent Health Holdings and an affiliate of TPG Global, LLC (along with its affiliates, “TPG”);
|
•
|
distributions that Evolent Health LLC will be required to make to us and to the other members of Evolent Health LLC;
|
•
|
our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;
|
•
|
different interests among our pre-IPO investors, or between us and our pre-IPO investors;
|
•
|
the terms of agreements between us and certain of our pre-IPO investors;
|
•
|
the conditional conversion feature of the 2025 Notes, which, if triggered, could require us to settle the 2025 Notes in cash;
|
•
|
the impact of the accounting method for convertible debt securities that may be settled in cash;
|
•
|
the potential volatility of our Class A common stock price;
|
•
|
the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale or if a large number of Class B common units are exchanged for shares of Class A common stock;
|
•
|
provisions in our second amended and restated certificate of incorporation and second amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;
|
•
|
the ability of certain of our investors to compete with us without restrictions;
|
•
|
provisions in our second amended and restated certificate of incorporation which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees;
|
•
|
our intention not to pay cash dividends on our Class A common stock;
|
•
|
our ability to maintain effective internal control over financial reporting;
|
•
|
our expectations regarding the additional management attention and costs that will be required as we have transitioned from an “emerging growth company” to a “large accelerated filer”; and
|
•
|
our lack of public company operating experience.
|
|
|
As of
|
|
|
As of
|
|
||||
|
June 30,
|
December 31,
|
||||||||
|
|
2019
|
|
|
2018
|
|
||||
ASSETS
|
|
|
|
|
|
|
||||
Current assets:
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
92,821
|
|
|
|
$
|
228,320
|
|
|
Restricted cash and restricted investments
|
|
38,619
|
|
|
|
154,718
|
|
|
||
Accounts receivable, net (amounts attributable to related parties: 2019 - $6,260; 2018 - $8,519)
|
|
71,379
|
|
|
|
80,208
|
|
|
||
Prepaid expenses and other current assets (amounts attributable to related parties: 2019 - $109; 2018 - $85)
|
|
32,810
|
|
|
|
22,618
|
|
|
||
Investments, at amortized cost
|
|
4,048
|
|
|
|
—
|
|
|
||
Contract assets
|
|
1,187
|
|
|
|
2,102
|
|
|
||
Total current assets
|
|
240,864
|
|
|
|
487,966
|
|
|
||
Restricted cash and restricted investments
|
|
6,539
|
|
|
|
6,105
|
|
|
||
Investments, at amortized cost
|
|
13,084
|
|
|
|
10,010
|
|
|
||
Investments in and advances to equity method investees
|
|
59,167
|
|
|
|
6,276
|
|
|
||
Property and equipment, net
|
|
80,217
|
|
|
|
73,628
|
|
|
||
Right-of-use assets - operating
|
|
76,712
|
|
|
|
—
|
|
|
||
Customer advance for regulatory capital requirements
|
|
40,000
|
|
|
|
—
|
|
|
||
Prepaid expenses and other noncurrent assets (amounts attributable to related parties: 2019 - $3,500; 2018 - $2,500)
|
|
10,947
|
|
|
|
15,028
|
|
|
||
Contract assets
|
|
1,491
|
|
|
|
961
|
|
|
||
Contract cost assets
|
|
24,485
|
|
|
|
19,147
|
|
|
||
Intangible assets, net
|
|
326,586
|
|
|
|
335,036
|
|
|
||
Goodwill
|
|
772,164
|
|
|
|
768,124
|
|
|
||
Total assets
|
|
$
|
1,652,256
|
|
|
|
$
|
1,722,281
|
|
|
|
|
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
Liabilities
|
|
|
|
|
|
|
||||
Current liabilities:
|
|
|
|
|
|
|
||||
Accounts payable (amounts attributable to related parties: 2019 - $3,950; 2018 - $1,564)
|
|
28,758
|
|
|
|
146,760
|
|
|
||
Accrued liabilities (amounts attributable to related parties: 2019 - $440; 2018 - $798)
|
|
52,631
|
|
|
|
48,957
|
|
|
||
Operating lease liabilities - current
|
|
4,649
|
|
|
|
—
|
|
|
||
Accrued compensation and employee benefits
|
|
26,860
|
|
|
|
25,460
|
|
|
||
Deferred revenue
|
|
26,923
|
|
|
|
20,584
|
|
|
||
Reserve for claims and performance-based arrangements (amounts attributable to related parties: 2019 - $5,894; 2018 - $0)
|
|
33,052
|
|
|
|
27,595
|
|
|
||
Total current liabilities
|
|
172,873
|
|
|
|
269,356
|
|
|
||
Long-term debt, net of discount
|
|
225,642
|
|
|
|
221,041
|
|
|
||
Other long-term liabilities
|
|
10,423
|
|
|
|
17,090
|
|
|
||
Operating lease liabilities - noncurrent
|
|
70,796
|
|
|
|
—
|
|
|
||
Deferred tax liabilities, net
|
|
25,766
|
|
|
|
25,438
|
|
|
||
Total liabilities
|
|
505,500
|
|
|
|
532,925
|
|
|
||
|
|
|
|
|
|
|
||||
Commitments and Contingencies (See Note 9)
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
Shareholders' Equity (Deficit)
|
|
|
|
|
|
|
||||
Class A common stock - $0.01 par value; 750,000,000 shares authorized as of June 30, 2019 and December 31, 2018;
|
|
|
|
|
|
|
||||
83,814,852 and 79,172,118 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
|
|
838
|
|
|
|
792
|
|
|
||
Class B common stock - $0.01 par value; 100,000,000 shares authorized as of June 30, 2019 and December 31, 2018;
|
|
|
|
|
|
|
||||
706,273 and 3,190,301 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
|
|
7
|
|
|
|
31
|
|
|
||
Additional paid-in capital
|
|
1,158,325
|
|
|
|
1,093,174
|
|
|
||
Accumulated other comprehensive income (loss)
|
|
(147
|
)
|
|
|
(182
|
)
|
|
||
Retained earnings (accumulated deficit)
|
|
(28,345
|
)
|
|
|
50,009
|
|
|
||
Total shareholders' equity (deficit) attributable to Evolent Health, Inc.
|
|
1,130,678
|
|
|
|
1,143,824
|
|
|
||
Non-controlling interests
|
|
16,078
|
|
|
|
45,532
|
|
|
||
Total shareholders' equity (deficit)
|
|
1,146,756
|
|
|
|
1,189,356
|
|
|
||
Total liabilities and shareholders' equity (deficit)
|
|
$
|
1,652,256
|
|
|
|
$
|
1,722,281
|
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Revenue
|
|
|
|
|
|
|
|
||||||||
Transformation services (1)
|
$
|
1,944
|
|
|
$
|
8,215
|
|
|
$
|
5,297
|
|
|
$
|
14,720
|
|
Platform and operations services (1)
|
144,522
|
|
|
113,346
|
|
|
291,814
|
|
|
223,164
|
|
||||
Premiums
|
45,493
|
|
|
22,737
|
|
|
92,604
|
|
|
46,128
|
|
||||
Total revenue
|
191,959
|
|
|
144,298
|
|
|
389,715
|
|
|
284,012
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Expenses
|
|
|
|
|
|
|
|
||||||||
Cost of revenue (exclusive of depreciation and amortization
|
|
|
|
|
|
|
|
||||||||
expenses presented separately below) (1)
|
108,383
|
|
|
69,003
|
|
|
225,824
|
|
|
140,978
|
|
||||
Claims expenses
|
36,085
|
|
|
18,428
|
|
|
73,842
|
|
|
35,177
|
|
||||
Selling, general and administrative expenses (1)
|
66,932
|
|
|
57,403
|
|
|
141,770
|
|
|
112,929
|
|
||||
Depreciation and amortization expenses
|
15,292
|
|
|
10,034
|
|
|
29,558
|
|
|
19,530
|
|
||||
(Gain) loss on disposal of assets
|
(9,600
|
)
|
|
—
|
|
|
(9,600
|
)
|
|
—
|
|
||||
Change in fair value of contingent consideration and indemnification asset
|
100
|
|
|
(1,604
|
)
|
|
200
|
|
|
(1,504
|
)
|
||||
Total operating expenses
|
217,192
|
|
|
153,264
|
|
|
461,594
|
|
|
307,110
|
|
||||
Operating income (loss)
|
(25,233
|
)
|
|
(8,966
|
)
|
|
(71,879
|
)
|
|
(23,098
|
)
|
||||
Interest income
|
842
|
|
|
878
|
|
|
1,902
|
|
|
1,950
|
|
||||
Interest expense
|
(3,620
|
)
|
|
(855
|
)
|
|
(7,182
|
)
|
|
(1,708
|
)
|
||||
Income (loss) from equity method investees
|
(1,904
|
)
|
|
(1,275
|
)
|
|
(2,328
|
)
|
|
(1,406
|
)
|
||||
Other income (expense), net
|
(587
|
)
|
|
78
|
|
|
(160
|
)
|
|
60
|
|
||||
Income (loss) before income taxes and non-controlling interests
|
(30,502
|
)
|
|
(10,140
|
)
|
|
(79,647
|
)
|
|
(24,202
|
)
|
||||
Provision (benefit) for income taxes
|
1,398
|
|
|
(109
|
)
|
|
902
|
|
|
(106
|
)
|
||||
Net income (loss)
|
(31,900
|
)
|
|
(10,031
|
)
|
|
(80,549
|
)
|
|
(24,096
|
)
|
||||
Net income (loss) attributable to non-controlling interests
|
(285
|
)
|
|
(115
|
)
|
|
(2,195
|
)
|
|
(554
|
)
|
||||
Net income (loss) attributable to Evolent Health, Inc.
|
$
|
(31,615
|
)
|
|
$
|
(9,916
|
)
|
|
$
|
(78,354
|
)
|
|
$
|
(23,542
|
)
|
|
|
|
|
|
|
|
|
||||||||
Earnings (Loss) Available for Common Shareholders
|
|
|
|
|
|
|
|
||||||||
Basic and Diluted
|
$
|
(31,615
|
)
|
|
$
|
(9,916
|
)
|
|
$
|
(78,354
|
)
|
|
$
|
(23,542
|
)
|
|
|
|
|
|
|
|
|
||||||||
Earnings (Loss) per Common Share
|
|
|
|
|
|
|
|
||||||||
Basic and Diluted
|
$
|
(0.38
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
(0.97
|
)
|
|
$
|
(0.31
|
)
|
|
|
|
|
|
|
|
|
||||||||
Weighted-Average Common Shares Outstanding
|
|
|
|
|
|
|
|
||||||||
Basic and Diluted
|
82,289
|
|
|
77,209
|
|
|
80,820
|
|
|
76,297
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive income (loss)
|
|
|
|
|
|
|
|
||||||||
Net income (loss)
|
$
|
(31,900
|
)
|
|
$
|
(10,031
|
)
|
|
$
|
(80,549
|
)
|
|
(24,096
|
)
|
|
Other comprehensive income (loss), net of taxes, related to:
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation adjustment
|
11
|
|
|
(148
|
)
|
|
35
|
|
|
(148
|
)
|
||||
Total comprehensive income (loss)
|
(31,889
|
)
|
|
(10,179
|
)
|
|
(80,514
|
)
|
|
(24,244
|
)
|
||||
Total comprehensive income (loss) attributable to non-controlling interests
|
(285
|
)
|
|
(115
|
)
|
|
(2,195
|
)
|
|
(554
|
)
|
||||
Total comprehensive income (loss) attributable to Evolent Health, Inc.
|
$
|
(31,604
|
)
|
|
$
|
(10,064
|
)
|
|
$
|
(78,319
|
)
|
|
$
|
(23,690
|
)
|
|
For the Six
|
||||||
|
Months Ended
|
||||||
|
June 30,
|
||||||
|
2019
|
|
2018
|
||||
Cash Flows from Operating Activities
|
|
|
|
||||
Net income (loss)
|
$
|
(80,549
|
)
|
|
$
|
(24,096
|
)
|
Adjustments to reconcile net income (loss) to net cash and restricted cash
|
|
|
|
||||
provided by (used in) operating activities:
|
|
|
|
||||
(Income) loss from equity method investees
|
2,328
|
|
|
1,406
|
|
||
(Gain) loss on disposal of assets
|
(9,600
|
)
|
|
—
|
|
||
Change in fair value of contingent consideration and indemnification asset
|
200
|
|
|
(1,504
|
)
|
||
Depreciation and amortization expenses
|
29,558
|
|
|
19,530
|
|
||
Amortization of deferred financing costs
|
4,600
|
|
|
459
|
|
||
Stock-based compensation expense
|
9,287
|
|
|
8,513
|
|
||
Deferred tax provision (benefit)
|
782
|
|
|
(171
|
)
|
||
Amortization of contract cost assets
|
2,773
|
|
|
1,166
|
|
||
Other
|
527
|
|
|
(55
|
)
|
||
Changes in assets and liabilities, net of acquisitions:
|
|
|
|
||||
Accounts receivables, net and contract assets
|
9,891
|
|
|
(21,286
|
)
|
||
Prepaid expenses and other current and noncurrent assets
|
(8,882
|
)
|
|
(12,753
|
)
|
||
Contract cost assets
|
(8,110
|
)
|
|
(762
|
)
|
||
Accounts payable
|
1,025
|
|
|
(342
|
)
|
||
Accrued liabilities
|
(4,167
|
)
|
|
6,140
|
|
||
Accrued compensation and employee benefits
|
1,394
|
|
|
(12,846
|
)
|
||
Deferred revenue
|
6,339
|
|
|
8,267
|
|
||
Reserves for claims and performance-based arrangements
|
5,457
|
|
|
9,466
|
|
||
ROU operating assets
|
(25,350
|
)
|
|
—
|
|
||
Operating lease liabilities
|
28,041
|
|
|
—
|
|
||
Other long-term liabilities
|
(4,786
|
)
|
|
864
|
|
||
Net cash and restricted cash provided by (used in) operating activities
|
(39,242
|
)
|
|
(18,004
|
)
|
||
|
|
|
|
||||
Cash Flows from Investing Activities
|
|
|
|
||||
Cash paid for asset acquisitions or business combinations
|
(6,000
|
)
|
|
(11,676
|
)
|
||
Customer advance for regulatory capital requirements
|
(45,400
|
)
|
|
—
|
|
||
Principal repayment of implementation funding loan and regulatory capital requirements
|
2,830
|
|
|
8,000
|
|
||
Amount received from escrow in asset acquisition
|
—
|
|
|
500
|
|
||
Purchases of investments
|
(7,122
|
)
|
|
—
|
|
||
Investments in and advances to equity method investees
|
(16,892
|
)
|
|
(4,000
|
)
|
||
Investments in internal-use software and purchases of property and equipment
|
(17,739
|
)
|
|
(20,243
|
)
|
||
Purchases of restricted investments
|
(493
|
)
|
|
—
|
|
||
Maturities of restricted investments
|
—
|
|
|
8,043
|
|
||
Net cash and restricted cash provided by (used in) investing activities
|
(90,816
|
)
|
|
(19,376
|
)
|
||
|
|
|
|
||||
Cash Flows from Financing Activities
|
|
|
|
||||
Changes in working capital balances related to claims processing on behalf of partners
|
(119,506
|
)
|
|
(7,258
|
)
|
||
Amount received from escrow in asset acquisition
|
500
|
|
|
—
|
|
||
Deferred financing costs related to 2025 Notes
|
(608
|
)
|
|
—
|
|
||
Proceeds from stock option exercises
|
948
|
|
|
4,692
|
|
||
Taxes withheld and paid for vesting of restricted stock units
|
(2,405
|
)
|
|
(1,099
|
)
|
||
Net cash and restricted cash provided by (used in) financing activities
|
(121,071
|
)
|
|
(3,665
|
)
|
||
Effect of exchange rate on cash and cash equivalents and restricted cash
|
(29
|
)
|
|
7
|
|
||
Net increase (decrease) in cash and cash equivalents and restricted cash
|
(251,158
|
)
|
|
(41,038
|
)
|
||
Cash and cash equivalents and restricted cash as of beginning-of-period
|
388,325
|
|
|
295,363
|
|
||
Cash and cash equivalents and restricted cash as of end-of-period
|
$
|
137,167
|
|
|
$
|
254,325
|
|
|
For the Three Months Ended June 30, 2019
|
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Accum-
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
ulated
|
|
|
Retained
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
Earnings
|
|
|
|
|
||||||||||||||||
|
Class A
|
|
Class B
|
|
Additional
|
|
Comprehensive
|
|
(Accum-
|
|
Non-
|
|
Total
|
||||||||||||||||||||||
|
Common Stock
|
|
Common Stock
|
|
Paid-in
|
|
|
Income
|
|
|
ulated
|
|
Controlling
|
|
Equity
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit)
|
|
Interests
|
|
(Deficit)
|
||||||||||||||||
Balance as of March 31, 2019
|
79,429
|
|
|
$
|
794
|
|
|
3,190
|
|
|
$
|
31
|
|
|
$
|
1,096,089
|
|
|
|
$
|
(158
|
)
|
|
|
$
|
3,270
|
|
|
$
|
50,100
|
|
|
$
|
1,150,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,362
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
4,362
|
|
|||||||
Exercise of stock options
|
93
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
822
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
823
|
|
|||||||
Restricted stock units vested, net of shares withheld for taxes
|
77
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
(223
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(222
|
)
|
|||||||
Shares issued for equity-method investments and asset acquisitions
|
1,732
|
|
|
18
|
|
|
—
|
|
|
—
|
|
|
23,538
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
23,556
|
|
|||||||
Exchange of Class B common stock
|
2,484
|
|
|
24
|
|
|
(2,484
|
)
|
|
(24
|
)
|
|
33,946
|
|
|
|
—
|
|
|
|
—
|
|
|
(33,946
|
)
|
|
—
|
|
|||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
11
|
|
|
|
—
|
|
|
—
|
|
|
11
|
|
|||||||
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
(31,615
|
)
|
|
(285
|
)
|
|
(31,900
|
)
|
|||||||
Reclassification of non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(209
|
)
|
|
|
—
|
|
|
|
—
|
|
|
209
|
|
|
—
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Balance as of June 30, 2019
|
83,815
|
|
|
$
|
838
|
|
|
706
|
|
|
$
|
7
|
|
|
$
|
1,158,325
|
|
|
|
$
|
(147
|
)
|
|
|
$
|
(28,345
|
)
|
|
$
|
16,078
|
|
|
$
|
1,146,756
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
For the Three Months Ended June 30, 2018
|
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Accum-
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
ulated
|
|
|
Retained
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
Earnings
|
|
|
|
|
||||||||||||||||
|
Class A
|
|
Class B
|
|
Additional
|
|
Comprehensive
|
|
(Accum-
|
|
Non-
|
|
Total
|
||||||||||||||||||||||
|
Common Stock
|
|
Common Stock
|
|
Paid-in
|
|
|
Income
|
|
|
ulated
|
|
Controlling
|
|
Equity
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit)
|
|
Interests
|
|
(Deficit)
|
||||||||||||||||
Balance as of March 31, 2018
|
76,979
|
|
|
$
|
770
|
|
|
881
|
|
|
$
|
9
|
|
|
$
|
953,322
|
|
|
|
$
|
—
|
|
|
|
$
|
89,041
|
|
|
$
|
11,772
|
|
|
$
|
1,054,914
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,718
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
4,718
|
|
|||||||
Exercise of stock options
|
412
|
|
|
4
|
|
|
—
|
|
|
—
|
|
|
3,227
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
3,231
|
|
|||||||
Restricted stock units vested, net of shares withheld for taxes
|
72
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
(300
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(299
|
)
|
|||||||
Exchange of Class B common stock
|
115
|
|
|
1
|
|
|
(115
|
)
|
|
(1
|
)
|
|
1,529
|
|
|
|
—
|
|
|
|
—
|
|
|
(1,529
|
)
|
|
—
|
|
|||||||
Settlement of indemnification asset
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,004
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(1,004
|
)
|
|||||||
Foreign Currency Translation Adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
(148
|
)
|
|
|
—
|
|
|
—
|
|
|
(148
|
)
|
|||||||
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
(9,916
|
)
|
|
(115
|
)
|
|
(10,031
|
)
|
|||||||
Reclassification of non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(20
|
)
|
|
|
—
|
|
|
|
—
|
|
|
20
|
|
|
—
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Balance as of June 30, 2018
|
77,578
|
|
|
$
|
776
|
|
|
766
|
|
|
$
|
8
|
|
|
$
|
961,472
|
|
|
|
$
|
(148
|
)
|
|
|
$
|
79,125
|
|
|
$
|
10,148
|
|
|
$
|
1,051,381
|
|
|
For the Six Months Ended June 30, 2019
|
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Accum-
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
ulated
|
|
|
Retained
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
Earnings
|
|
|
|
|
||||||||||||||||
|
Class A
|
|
Class B
|
|
Additional
|
|
Comprehensive
|
|
(Accum-
|
|
Non-
|
|
Total
|
||||||||||||||||||||||
|
Common Stock
|
|
Common Stock
|
|
Paid-in
|
|
|
Income
|
|
|
ulated
|
|
Controlling
|
|
Equity
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit)
|
|
Interests
|
|
(Deficit)
|
||||||||||||||||
Balance as of December 31, 2018
|
79,172
|
|
|
$
|
792
|
|
|
3,190
|
|
|
$
|
31
|
|
|
$
|
1,093,174
|
|
|
|
$
|
(182
|
)
|
|
|
$
|
50,009
|
|
|
$
|
45,532
|
|
|
$
|
1,189,356
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8,515
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
8,515
|
|
|||||||
Exercise of stock options
|
104
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
947
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
948
|
|
|||||||
Restricted stock units vested, net of shares withheld for taxes
|
280
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
(2,408
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(2,405
|
)
|
|||||||
Class A common stock issued for Passport earn-out
|
43
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
800
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
800
|
|
|||||||
Amount attributable to NCI from 2019 business combination
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
6,500
|
|
|
6,500
|
|
|||||||
Shares issued for equity-method investments and asset acquisitions
|
1,732
|
|
|
18
|
|
|
—
|
|
|
—
|
|
|
23,538
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
23,556
|
|
|||||||
Exchange of Class B common stock
|
2,484
|
|
|
24
|
|
|
(2,484
|
)
|
|
(24
|
)
|
|
33,946
|
|
|
|
—
|
|
|
|
—
|
|
|
(33,946
|
)
|
|
—
|
|
|||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
35
|
|
|
|
—
|
|
|
—
|
|
|
35
|
|
|||||||
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
(78,354
|
)
|
|
(2,195
|
)
|
|
(80,549
|
)
|
|||||||
Reclassification of non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(187
|
)
|
|
|
—
|
|
|
|
—
|
|
|
187
|
|
|
—
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Balance as of June 30, 2019
|
83,815
|
|
|
$
|
838
|
|
|
706
|
|
|
$
|
7
|
|
|
$
|
1,158,325
|
|
|
|
$
|
(147
|
)
|
|
|
$
|
(28,345
|
)
|
|
$
|
16,078
|
|
|
$
|
1,146,756
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
For the Six Months Ended June 30, 2018
|
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Accum-
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
ulated
|
|
|
Retained
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
Earnings
|
|
|
|
|
||||||||||||||||
|
Class A
|
|
Class B
|
|
Additional
|
|
Comprehensive
|
|
(Accum-
|
|
Non-
|
|
Total
|
||||||||||||||||||||||
|
Common Stock
|
|
Common Stock
|
|
Paid-in
|
|
|
Income
|
|
|
ulated
|
|
Controlling
|
|
Equity
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit)
|
|
Interests
|
|
(Deficit)
|
||||||||||||||||
Balance as of December 31, 2017
|
74,723
|
|
|
$
|
747
|
|
|
2,654
|
|
|
$
|
27
|
|
|
$
|
924,153
|
|
|
|
$
|
—
|
|
|
|
$
|
85,952
|
|
|
$
|
35,427
|
|
|
$
|
1,046,306
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Cumulative-effect adjustment from adoption of ASC 606
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
16,715
|
|
|
594
|
|
|
17,309
|
|
|||||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8,513
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
8,513
|
|
|||||||
Exercise of stock options
|
766
|
|
|
8
|
|
|
—
|
|
|
—
|
|
|
4,684
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
4,692
|
|
|||||||
Restricted stock units vested, net of shares withheld for taxes
|
201
|
|
|
2
|
|
|
—
|
|
|
—
|
|
|
(1,101
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(1,099
|
)
|
|||||||
Exchange of Class B common stock
|
1,888
|
|
|
19
|
|
|
(1,888
|
)
|
|
(19
|
)
|
|
25,334
|
|
|
|
—
|
|
|
|
—
|
|
|
(25,334
|
)
|
|
—
|
|
|||||||
Tax impact of Class B Exchanges
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
908
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
908
|
|
|||||||
Settlement of indemnification asset
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,004
|
)
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
(1,004
|
)
|
|||||||
Foreign Currency Translation Adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
(148
|
)
|
|
|
—
|
|
|
—
|
|
|
(148
|
)
|
|||||||
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
(23,542
|
)
|
|
(554
|
)
|
|
(24,096
|
)
|
|||||||
Reclassification of non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15
|
)
|
|
|
—
|
|
|
|
—
|
|
|
15
|
|
|
—
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Balance as of June 30, 2018
|
77,578
|
|
|
$
|
776
|
|
|
766
|
|
|
$
|
8
|
|
|
$
|
961,472
|
|
|
|
$
|
(148
|
)
|
|
|
$
|
79,125
|
|
|
$
|
10,148
|
|
|
$
|
1,051,381
|
|
•
|
Identify the contract(s) with a customer
|
•
|
Identify the performance obligations in the contract
|
•
|
Determine the transaction price
|
•
|
Allocate the transaction price to performance obligations
|
•
|
Recognize revenue when (or as) the entity satisfies a performance obligation
|
|
|
As of
|
|
|
As of
|
|
||||
|
June 30,
|
December 31,
|
||||||||
|
|
2019
|
|
|
2018
|
|
||||
Collateral for letters of credit for facility leases (1)
|
|
$
|
3,610
|
|
|
|
$
|
3,710
|
|
|
Collateral with financial institutions (2)
|
|
37,876
|
|
|
|
34,142
|
|
|
||
Claims processing services (3)
|
|
2,933
|
|
|
|
122,439
|
|
|
||
Other
|
|
739
|
|
|
|
532
|
|
|
||
Total restricted cash and restricted investments
|
|
45,158
|
|
|
|
160,823
|
|
|
||
|
|
|
|
|
|
|
||||
Current restricted investments
|
|
702
|
|
|
|
211
|
|
|
||
Current restricted cash
|
|
37,917
|
|
|
|
154,507
|
|
|
||
Total current restricted cash and restricted investments
|
|
38,619
|
|
|
|
154,718
|
|
|
||
|
|
|
|
|
|
|
||||
Noncurrent restricted investments
|
|
110
|
|
|
|
607
|
|
|
||
Noncurrent restricted cash
|
|
6,429
|
|
|
|
5,498
|
|
|
||
Total noncurrent restricted cash and
|
|
|
|
|
|
|
||||
restricted investments
|
|
$
|
6,539
|
|
|
|
$
|
6,105
|
|
|
|
|
As of June 30,
|
|
|||||||
|
|
2019
|
|
|
2018
|
|
||||
Cash and cash equivalents
|
|
$
|
92,821
|
|
|
|
$
|
197,983
|
|
|
Restricted cash and restricted investments
|
|
45,158
|
|
|
|
57,054
|
|
|
||
Restricted investments included in
|
|
|
|
|
|
|
||||
restricted cash and restricted investments
|
|
(812
|
)
|
|
|
(712
|
)
|
|
||
Total cash and cash equivalents and restricted cash
|
|
|
|
|
|
|
||||
shown in the consolidated statements of cash flows
|
|
$
|
137,167
|
|
|
|
$
|
254,325
|
|
|
Corporate trade name
|
10-20 years
|
Customer relationships
|
10-25 years
|
Technology
|
5 years
|
Provider network contracts
|
5 years
|
Purchase consideration:
|
|
||
Cash
|
$
|
124,652
|
|
Fair value of Class B common stock issued
|
83,173
|
|
|
Fair value of contingent consideration
|
3,200
|
|
|
Total consideration
|
$
|
211,025
|
|
|
|
||
Tangible assets acquired:
|
|
||
Cash and cash equivalents
|
$
|
5,963
|
|
Accounts receivable
|
5,559
|
|
|
Prepaid expenses and other current assets
|
7,901
|
|
|
Property and equipment
|
381
|
|
|
Other noncurrent assets
|
148
|
|
|
|
|
||
Identifiable intangible assets acquired:
|
|
||
Customer relationships
|
72,500
|
|
|
Technology
|
27,000
|
|
|
Corporate trade name
|
4,300
|
|
|
Provider network contracts
|
9,600
|
|
|
|
|
||
Liabilities assumed:
|
|
||
Accounts payable
|
1,167
|
|
|
Accrued liabilities
|
1,494
|
|
|
Accrued compensation and employee benefits
|
3,966
|
|
|
Reserves for claims and performance-based arrangements
|
18,631
|
|
|
Deferred tax liabilities
|
24,041
|
|
|
Other long-term liabilities
|
6,138
|
|
|
|
|
||
Goodwill
|
133,110
|
|
|
Net assets acquired
|
$
|
211,025
|
|
Purchase consideration
|
|
||
Cash paid to NMHC
|
$
|
10,000
|
|
Cash paid to escrow agent
|
252
|
|
|
Total consideration
|
$
|
10,252
|
|
|
|
||
Identifiable intangible assets acquired and liabilities assumed
|
|
||
Customer relationships
|
$
|
2,700
|
|
Provider network contracts
|
2,300
|
|
|
Above market lease
|
(100
|
)
|
|
Accrued compensation and employee benefits
|
(474
|
)
|
|
|
|
||
Goodwill
|
5,826
|
|
|
Net assets acquired
|
$
|
10,252
|
|
•
|
Remove transaction costs related to the New Century Health transaction of $1.6 million recorded during 2018 and reclassify such amounts to 2017;
|
•
|
Record amortization expenses related to intangible assets beginning on January 1, 2017, for intangibles acquired as part of the New Century Health and True Health transactions;
|
•
|
Record revenue and expenses related to the NMHC MSA beginning January 1, 2017;
|
•
|
Record stock-based compensation expense beginning on January 1, 2017, for equity awards granted as part of the New Century Health transaction; and
|
•
|
Record the issuance of Class B common shares as part of the New Century Health transaction as of January 1, 2017.
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Revenue
|
$
|
191,959
|
|
|
$
|
189,572
|
|
|
$
|
389,715
|
|
|
$
|
374,203
|
|
Net income (loss)
|
(31,900
|
)
|
|
(10,427
|
)
|
|
(80,549
|
)
|
|
(25,312
|
)
|
||||
Net income (loss) attributable to non-controlling interests
|
(415
|
)
|
|
(511
|
)
|
|
(2,075
|
)
|
|
(1,446
|
)
|
||||
Net income (loss) attributable to Evolent Health, Inc.
|
(31,485
|
)
|
|
(9,916
|
)
|
|
(78,474
|
)
|
|
(23,866
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income (loss) per Common Share available to common shareholders
|
|
|
|
|
|
|
|
||||||||
Basic and Diluted
|
$
|
(0.38
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
(0.97
|
)
|
|
$
|
(0.31
|
)
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
|
June 30,
|
|
June 30,
|
||||||||||||
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Services Revenue
|
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
|
$
|
1,944
|
|
|
$
|
8,215
|
|
|
$
|
5,297
|
|
|
$
|
14,720
|
|
Platform and operations services
|
|
143,631
|
|
|
110,836
|
|
|
290,887
|
|
|
219,284
|
|
|
|
As of
|
|
|
As of
|
|
||||
|
June 30,
|
December 31,
|
||||||||
|
|
2019
|
|
2018
|
||||||
Short-term receivables (1)
|
|
$
|
69,522
|
|
|
|
$
|
78,380
|
|
|
Long-term receivables (1)
|
|
6,550
|
|
|
|
6,550
|
|
|
||
Short-term contract assets
|
|
1,187
|
|
|
|
2,102
|
|
|
||
Long-term contract assets
|
|
1,491
|
|
|
|
961
|
|
|
||
Short-term deferred revenue
|
|
26,923
|
|
|
|
20,584
|
|
|
||
Long-term deferred revenue
|
|
256
|
|
|
|
1,502
|
|
|
Contract assets
|
|
|
|
||
Balance as of beginning-of-period
|
|
$
|
3,063
|
|
|
Reclass to receivables, as the right
|
|
|
|
||
to consideration becomes unconditional
|
|
(1,482
|
)
|
|
|
Contract assets recognized, net of
|
|
|
|
||
reclass to receivables
|
|
1,097
|
|
|
|
Balance as of end-of-period
|
|
$
|
2,678
|
|
|
|
|
|
|
||
Deferred revenue
|
|
|
|
||
Balance as of beginning-of-period
|
|
$
|
22,086
|
|
|
Reclass to revenue, as a result
|
|
|
|
||
of performance obligations satisfied
|
|
(12,714
|
)
|
|
|
Cash received in advance of satisfaction
|
|
|
|
||
of performance obligations
|
|
17,807
|
|
|
|
Balance as of end-of-period
|
|
$
|
27,179
|
|
|
|
|
As of
|
|
|
As of
|
|
||||
|
June 30,
|
December 31,
|
||||||||
|
|
2019
|
|
|
2018
|
|
||||
Computer hardware
|
|
$
|
11,131
|
|
|
|
$
|
10,421
|
|
|
Furniture and equipment
|
|
3,255
|
|
|
|
3,187
|
|
|
||
Internal-use software development costs
|
|
98,523
|
|
|
|
81,640
|
|
|
||
Leasehold improvements
|
|
9,945
|
|
|
|
10,118
|
|
|
||
Total property and equipment
|
|
122,854
|
|
|
|
105,366
|
|
|
||
Accumulated depreciation and amortization
|
|
(42,637
|
)
|
|
|
(31,738
|
)
|
|
||
Total property and equipment, net
|
|
$
|
80,217
|
|
|
|
$
|
73,628
|
|
|
|
|
For the Six Months Ended June 30, 2019
|
|
||||||||||||
|
|
Services
|
|
|
True Health
|
|
Consolidated
|
||||||||
Balance as of beginning-of-period (1)
|
|
$
|
762,419
|
|
|
|
$
|
5,705
|
|
|
|
$
|
768,124
|
|
|
Goodwill Acquired
|
|
3,429
|
|
|
|
—
|
|
|
|
3,429
|
|
|
|||
Measurement period adjustments (2)
|
|
596
|
|
|
|
—
|
|
|
|
596
|
|
|
|||
Foreign currency translation
|
|
15
|
|
|
|
—
|
|
|
|
15
|
|
|
|||
Balance as of end-of-period
|
|
$
|
766,459
|
|
|
|
$
|
5,705
|
|
|
|
$
|
772,164
|
|
|
|
|
For the Year Ended December 31, 2018
|
|
||||||||||||
|
|
Services
|
|
|
True Health
|
|
Consolidated
|
||||||||
Balance as of beginning-of-period (1)
|
|
$
|
628,186
|
|
|
|
$
|
—
|
|
|
|
$
|
628,186
|
|
|
Goodwill Acquired (2)
|
|
134,343
|
|
|
|
5,826
|
|
|
|
140,169
|
|
|
|||
Measurement period adjustments (3)
|
|
4
|
|
|
|
(121
|
)
|
|
|
(117
|
)
|
|
|||
Foreign currency translation (4)
|
|
(114
|
)
|
|
|
—
|
|
|
|
(114
|
)
|
|
|||
Balance as of end-of-period
|
|
$
|
762,419
|
|
|
|
$
|
5,705
|
|
|
|
$
|
768,124
|
|
|
|
|
As of June 30, 2019
|
||||||||||||
|
|
Weighted-
|
|
|
|
|
|
|
||||||
|
|
Average
|
|
Gross
|
|
|
|
Net
|
||||||
|
Remaining
|
Carrying
|
Accumulated
|
Carrying
|
||||||||||
|
Useful Life
|
Amount
|
Amortization
|
Value
|
||||||||||
Corporate trade name
|
|
14.7
|
|
$
|
23,300
|
|
|
$
|
4,201
|
|
|
$
|
19,099
|
|
Customer relationships
|
|
17.3
|
|
291,519
|
|
|
36,967
|
|
|
254,552
|
|
|||
Technology
|
|
2.5
|
|
82,922
|
|
|
40,761
|
|
|
42,161
|
|
|||
Below market lease, net
|
|
3.6
|
|
4,097
|
|
|
3,093
|
|
|
1,004
|
|
|||
Provider network contracts
|
|
4.1
|
|
11,900
|
|
|
2,130
|
|
|
9,770
|
|
|||
Total
|
|
|
|
$
|
413,738
|
|
|
$
|
87,152
|
|
|
$
|
326,586
|
|
|
|
As of December 31, 2018
|
||||||||||||
|
|
Weighted-
|
|
|
|
|
|
|
||||||
|
|
Average
|
|
Gross
|
|
|
|
Net
|
||||||
|
Remaining
|
Carrying
|
Accumulated
|
Carrying
|
||||||||||
|
Useful Life
|
Amount
|
Amortization
|
Value
|
||||||||||
Corporate trade name
|
|
15.2
|
|
$
|
23,300
|
|
|
$
|
3,511
|
|
|
$
|
19,789
|
|
Customer relationships
|
|
18.1
|
|
281,219
|
|
|
29,184
|
|
|
252,035
|
|
|||
Technology
|
|
3.0
|
|
82,922
|
|
|
31,764
|
|
|
51,158
|
|
|||
Below market lease, net
|
|
4.0
|
|
4,097
|
|
|
3,003
|
|
|
1,094
|
|
|||
Provider network contracts
|
|
4.6
|
|
11,900
|
|
|
940
|
|
|
10,960
|
|
|||
Total
|
|
|
|
$
|
403,438
|
|
|
$
|
68,402
|
|
|
$
|
335,036
|
|
2019
|
$
|
18,774
|
|
2020
|
33,309
|
|
|
2021
|
29,173
|
|
|
2022
|
25,292
|
|
|
2023
|
22,528
|
|
|
Thereafter
|
197,510
|
|
|
Total
|
$
|
326,586
|
|
|
|
As of
|
|
|
As of
|
|
||||
|
June 30,
|
December 31,
|
||||||||
|
|
2019
|
|
|
2018
|
|
||||
2025 Notes
|
|
|
|
|
|
|
||||
Carrying value
|
|
$
|
102,871
|
|
|
|
$
|
98,730
|
|
|
Unamortized debt discount and
|
|
|
|
|
|
|
||||
issuance costs allocated to debt
|
|
69,629
|
|
|
|
73,770
|
|
|
||
Principal amount
|
|
$
|
172,500
|
|
|
|
$
|
172,500
|
|
|
Remaining amortization period (years)
|
|
6.3
|
|
|
|
6.8
|
|
|
||
|
|
|
|
|
|
|
||||
2021 Notes
|
|
|
|
|
|
|
||||
Carrying value
|
|
$
|
122,771
|
|
|
|
$
|
122,311
|
|
|
Unamortized issuance costs
|
|
2,229
|
|
|
|
2,689
|
|
|
||
Principal amount
|
|
$
|
125,000
|
|
|
|
$
|
125,000
|
|
|
Remaining amortization period (years)
|
|
2.4
|
|
|
|
2.9
|
|
|
Reinsurance premiums assumed
|
$
|
48,828
|
|
Claims assumed
|
41,424
|
|
|
Claims-related administrative expenses
|
8,219
|
|
|
Increase (decrease) in reserves for claims and performance-based arrangements
|
|
||
attributable to the Reinsurance Agreement
|
815
|
|
|
Reserves for claims and performance-based arrangements attributable to the
|
|
||
Reinsurance Agreement at the beginning of the period
|
1,243
|
|
|
Reinsurance payments
|
1,235
|
|
|
(Receivables) Payables for claims and performance-based arrangements
|
|
||
attributable to the Reinsurance Agreement at the end of the period
|
$
|
823
|
|
•
|
the timing of the exchanges and the price of the Class A shares at the time of the transaction, triggering a tax basis increase in the Company’s asset and a corresponding benefit to be realized under the TRA; and
|
•
|
the amount and timing of our taxable income - the Company will be required to pay 85% of the tax savings as and when realized, if any. If the Company does not have taxable income, it will not be required to make payments under the TRA for that taxable year because no tax savings were actually realized.
|
|
|
As of
|
|
|
As of
|
|
||
|
June 30,
|
December 31,
|
||||||
|
|
2019
|
|
|
2018
|
|
||
Customer C
|
|
20.3
|
%
|
|
|
23.3
|
%
|
|
Customer D
|
|
15.3
|
%
|
|
|
*
|
|
|
|
|
For the Three
|
|
For the Six
|
||||||||
|
|
Months Ended
|
|
Months Ended
|
||||||||
|
|
June 30,
|
|
June 30,
|
||||||||
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||
Customer A
|
|
13.2
|
%
|
|
*
|
|
|
13.6
|
%
|
|
*
|
|
Customer B
|
|
13.2
|
%
|
|
18.0
|
%
|
|
13.1
|
%
|
|
19.0
|
%
|
Customer C
|
|
*
|
|
|
10.0
|
%
|
|
*
|
|
|
10.3
|
%
|
|
For the Three
|
For the Six
|
||||||||
|
Months Ended
|
Months Ended
|
||||||||
|
|
June 30,
|
|
|
June 30,
|
|
||||
|
|
2019
|
|
|
2019
|
|
||||
Operating lease cost
|
|
$
|
3,838
|
|
|
|
$
|
7,119
|
|
|
Variable lease cost
|
|
1,121
|
|
|
|
2,576
|
|
|
||
Total lease cost
|
|
$
|
4,959
|
|
|
|
$
|
9,695
|
|
|
|
Operating lease
|
||||
|
expense (1)
|
||||
2019
|
|
$
|
4,289
|
|
|
2020
|
|
10,404
|
|
|
|
2021
|
|
10,503
|
|
|
|
2022
|
|
9,389
|
|
|
|
2023
|
|
9,283
|
|
|
|
2024 and thereafter
|
|
61,156
|
|
|
|
Total lease payments
|
|
105,024
|
|
|
|
Less:
|
|
|
|
||
Interest
|
|
29,579
|
|
|
|
Present value of lease liabilities
|
|
75,445
|
|
|
|
|
As of
|
|
|
|
June 30,
|
|
|
|
2019
|
|
Weighted average discount rate
|
|
6.25
|
%
|
Weighted average remaining lease term
|
|
10.0
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Net income (loss)
|
$
|
(31,900
|
)
|
|
$
|
(10,031
|
)
|
|
$
|
(80,549
|
)
|
|
$
|
(24,096
|
)
|
Less:
|
|
|
|
|
|
|
|
||||||||
Net income (loss) attributable to non-controlling interests
|
(285
|
)
|
|
(115
|
)
|
|
(2,195
|
)
|
|
(554
|
)
|
||||
Net income (loss) available for common shareholders (1) (2)
|
$
|
(31,615
|
)
|
|
$
|
(9,916
|
)
|
|
$
|
(78,354
|
)
|
|
$
|
(23,542
|
)
|
|
|
|
|
|
|
|
|
||||||||
Weighted-average common shares outstanding (2) (3)
|
82,289
|
|
|
77,209
|
|
|
80,820
|
|
|
76,297
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Earnings (Loss) per Common Share
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
(0.38
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
(0.97
|
)
|
|
$
|
(0.31
|
)
|
Diluted
|
(0.38
|
)
|
|
(0.13
|
)
|
|
(0.97
|
)
|
|
(0.31
|
)
|
(1)
|
For periods of net loss, net income (loss) available for common shareholders is the same for both basic and diluted purposes.
|
(2)
|
Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share.
|
(3)
|
For periods of net loss, shares used in the earnings (loss) per common share calculation represent basic shares as using diluted shares would be anti-dilutive.
|
|
For the Three
|
|
For the Six
|
||||||||
|
Months Ended
|
|
Months Ended
|
||||||||
|
June 30,
|
|
June 30,
|
||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||
Exchangeable Class B common stock
|
1,080
|
|
|
862
|
|
|
2,129
|
|
|
1,498
|
|
Restricted stock units ("RSUs"), performance-based RSUs
|
|
|
|
|
|
|
|
||||
and leveraged stock units ("LSUs")
|
985
|
|
|
938
|
|
|
1,014
|
|
|
784
|
|
Stock options and performance-based stock options
|
1,495
|
|
|
2,591
|
|
|
1,729
|
|
|
2,378
|
|
Convertible senior notes
|
10,361
|
|
|
5,201
|
|
|
10,361
|
|
|
5,201
|
|
Total
|
13,921
|
|
|
9,592
|
|
|
15,233
|
|
|
9,861
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Award Type
|
|
|
|
|
|
|
|
||||||||
Stock options
|
$
|
903
|
|
|
$
|
2,639
|
|
|
$
|
2,263
|
|
|
$
|
4,870
|
|
Performance-based stock options
|
112
|
|
|
111
|
|
|
222
|
|
|
221
|
|
||||
RSUs
|
2,630
|
|
|
1,968
|
|
|
5,060
|
|
|
3,422
|
|
||||
Performance-based RSUs
|
388
|
|
|
—
|
|
|
772
|
|
|
—
|
|
||||
LSUs
|
717
|
|
|
—
|
|
|
970
|
|
|
—
|
|
||||
Total
|
$
|
4,750
|
|
|
$
|
4,718
|
|
|
$
|
9,287
|
|
|
$
|
8,513
|
|
|
|
|
|
|
|
|
|
||||||||
Line Item
|
|
|
|
|
|
|
|
||||||||
Cost of revenue
|
$
|
891
|
|
|
$
|
438
|
|
|
$
|
1,682
|
|
|
$
|
754
|
|
Selling, general and
|
|
|
|
|
|
|
|
||||||||
administrative expenses
|
3,859
|
|
|
4,280
|
|
|
7,605
|
|
|
7,759
|
|
||||
Total
|
$
|
4,750
|
|
|
$
|
4,718
|
|
|
$
|
9,287
|
|
|
$
|
8,513
|
|
|
For the Three
|
|
For the Six
|
||||||||
|
Months Ended
|
|
Months Ended
|
||||||||
|
June 30,
|
|
June 30,
|
||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||
Stock options
|
18
|
|
|
89
|
|
|
399
|
|
|
1,050
|
|
RSUs
|
17
|
|
|
85
|
|
|
518
|
|
|
838
|
|
LSUs
|
—
|
|
|
—
|
|
|
720
|
|
|
—
|
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
|
June 30,
|
|
June 30,
|
||||||||||||
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Provision (benefit) for income taxes
|
|
$
|
1,398
|
|
|
$
|
(109
|
)
|
|
$
|
902
|
|
|
$
|
(106
|
)
|
Effective tax rate
|
|
(4.6
|
)%
|
|
1.1
|
%
|
|
(1.1
|
)%
|
|
0.4
|
%
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Non-controlling interests as of beginning-of-period
|
$
|
50,100
|
|
|
$
|
11,772
|
|
|
$
|
45,532
|
|
|
$
|
35,427
|
|
Cumulative-effect adjustment from adoption of new accounting principle
|
—
|
|
|
—
|
|
|
—
|
|
|
594
|
|
||||
Decrease in non-controlling interests as a result of Class B Exchanges
|
(33,946
|
)
|
|
(1,529
|
)
|
|
(33,946
|
)
|
|
(25,334
|
)
|
||||
Amount attributable to NCI from 2019 business combination
|
—
|
|
|
—
|
|
|
6,500
|
|
|
—
|
|
||||
Net income (loss) attributable to non-controlling interests
|
(285
|
)
|
|
(115
|
)
|
|
(2,195
|
)
|
|
(554
|
)
|
||||
Reclassification of non-controlling interests
|
209
|
|
|
20
|
|
|
187
|
|
|
15
|
|
||||
Non-controlling interests as of end-of-period
|
$
|
16,078
|
|
|
$
|
10,148
|
|
|
$
|
16,078
|
|
|
$
|
10,148
|
|
•
|
Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;
|
•
|
Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and
|
•
|
Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.
|
|
As of June 30, 2019
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets
|
|
|
|
|
|
|
|
||||||||
Cash and cash equivalents (1)
|
$
|
5,756
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
5,756
|
|
Restricted cash and restricted investments (1)
|
34,957
|
|
|
—
|
|
|
—
|
|
|
34,957
|
|
||||
Total
|
$
|
40,713
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
40,713
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities
|
|
|
|
|
|
|
|
||||||||
Contingent consideration (2)
|
—
|
|
|
—
|
|
|
14,100
|
|
|
14,100
|
|
|
As of December 31, 2018
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets
|
|
|
|
|
|
|
|
||||||||
Cash and cash equivalents (1)
|
$
|
11,391
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
11,391
|
|
Restricted cash and restricted investments (1)
|
31,226
|
|
|
—
|
|
|
—
|
|
|
31,226
|
|
||||
Total
|
$
|
42,617
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
42,617
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities
|
|
|
|
|
|
|
|
||||||||
Contingent consideration (2)
|
—
|
|
|
—
|
|
|
8,800
|
|
|
8,800
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Balance as of beginning-of-period
|
$
|
8,100
|
|
|
$
|
8,800
|
|
|
$
|
8,800
|
|
|
$
|
8,700
|
|
Additions(1)
|
5,900
|
|
|
—
|
|
|
5,900
|
|
|
—
|
|
||||
Settlements
|
—
|
|
|
—
|
|
|
(800
|
)
|
|
—
|
|
||||
Realized and unrealized (gains) losses, net
|
100
|
|
|
(600
|
)
|
|
200
|
|
|
(500
|
)
|
||||
Balance as of end-of-period
|
$
|
14,100
|
|
|
$
|
8,200
|
|
|
$
|
14,100
|
|
|
$
|
8,200
|
|
|
As of June 30, 2019
|
|
|||||||||
|
Fair
|
|
Valuation
|
|
Significant
|
|
Assumption or
|
|
|||
|
Value
|
|
Technique
|
|
Unobservable Inputs
|
|
Input Ranges
|
|
|||
Passport contingent
|
|
|
|
|
|
|
|
|
|||
consideration
|
$
|
5,000
|
|
|
Real options approach
|
|
Risk-adjusted recurring revenue CAGR
|
|
103.9
|
%
|
(1)
|
|
|
|
|
|
Discount rate
|
|
5.5% - 6.5%
|
|
|
||
|
|
|
|
|
|
|
|
|
|||
New Century Health
|
|
|
|
|
|
|
|
|
|||
contingent consideration
|
$
|
3,200
|
|
|
Real options approach
|
|
Risk-neutral probability exceeds threshold
|
|
39.0
|
%
|
(2)
|
|
|
|
|
|
Risk-neutral probability meets earn-out cap
|
|
24.0
|
%
|
(2)
|
||
|
|
|
|
|
|
|
|
|
|||
GlobalHealth
|
|
|
|
|
|
|
|
|
|||
contingent consideration
|
$
|
5,900
|
|
|
Management estimate
|
|
Stock price period
|
|
May - June 2019
|
|
|
|
As of December 31, 2018
|
|
|||||||||
|
Fair
|
|
Valuation
|
|
Significant
|
|
Assumption or
|
|
|||
|
Value
|
|
Technique
|
|
Unobservable Inputs
|
|
Input Ranges
|
|
|||
Passport contingent
|
|
|
|
|
|
|
|
|
|||
consideration
|
$
|
5,600
|
|
|
Real options approach
|
|
Risk-adjusted recurring revenue CAGR
|
|
103.9
|
%
|
(1)
|
|
|
|
|
|
Discount rate
|
|
5.5% - 6.5%
|
|
|
||
|
|
|
|
|
|
|
|
|
|||
New Century Health
|
|
|
|
|
|
|
|
|
|||
contingent consideration
|
$
|
3,200
|
|
|
Real options approach
|
|
Risk-neutral probability exceeds threshold
|
|
39.0
|
%
|
(2)
|
|
|
|
|
|
Risk-neutral probability meets earn-out cap
|
|
24.0
|
%
|
(2)
|
(2)
|
These amounts represent 1) the probability that New Century Health will achieve at least the minimum level of operating results in 2019 to earn any contingent consideration (39.0%) and 2) the probability that New Century Health will achieve 2019 operating results in excess of the maximum amount of contingent consideration payable (24.0%). The risk-neutral probability rates were determined by projecting theoretical 2019 operating results using a simulation with one million trials.
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
June 30,
|
|
June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Revenue
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
$
|
41
|
|
|
$
|
748
|
|
|
$
|
1,200
|
|
|
$
|
780
|
|
Platform and operations services
|
16,874
|
|
|
7,601
|
|
|
29,818
|
|
|
14,892
|
|
||||
Expenses
|
|
|
|
|
|
|
|
||||||||
Cost of revenue (exclusive of depreciation and amortization expenses)
|
6,657
|
|
|
1,262
|
|
|
14,487
|
|
|
4,452
|
|
||||
Selling, general and administrative expenses
|
386
|
|
|
280
|
|
|
542
|
|
|
379
|
|
•
|
Services, which consists of our technology-enabled value-based care services, specialty care management services and comprehensive health plan administration services; and
|
•
|
True Health, which consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses.
|
|
|
|
|
|
|
|
Intersegment
|
|
|
|
|
||||||||||
|
|
Services
|
|
True Health
|
Eliminations
|
Consolidated
|
|
||||||||||||||
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Three Months Ended June 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
|
$
|
1,944
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
1,944
|
|
|
|
Platform and operations
|
|
147,599
|
|
|
|
—
|
|
|
|
(3,077
|
)
|
|
|
144,522
|
|
|
|
||||
Services revenue
|
|
149,543
|
|
|
|
—
|
|
|
|
(3,077
|
)
|
|
|
146,466
|
|
|
|
||||
True Health:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Premiums
|
|
—
|
|
|
|
45,764
|
|
|
|
(271
|
)
|
|
|
45,493
|
|
|
|
||||
Total revenue
|
|
$
|
149,543
|
|
|
|
$
|
45,764
|
|
|
|
$
|
(3,348
|
)
|
|
|
$
|
191,959
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Three Months Ended June 30, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
|
$
|
8,215
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
8,215
|
|
|
|
Platform and operations
|
|
116,961
|
|
|
|
—
|
|
|
|
(3,615
|
)
|
|
|
113,346
|
|
|
|
||||
Services revenue
|
|
125,176
|
|
|
|
—
|
|
|
|
(3,615
|
)
|
|
|
121,561
|
|
|
|
||||
True Health:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Premiums
|
|
—
|
|
|
|
22,939
|
|
|
|
(202
|
)
|
|
|
22,737
|
|
|
|
||||
Total revenue
|
|
$
|
125,176
|
|
|
|
$
|
22,939
|
|
|
|
$
|
(3,817
|
)
|
|
|
$
|
144,298
|
|
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
||||||
|
|
Services
|
|
True Health
|
Total
|
|
||||||||||
Three Months Ended June 30, 2019
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA
|
|
$
|
(8,797
|
)
|
|
|
$
|
1,123
|
|
|
|
$
|
(7,674
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Three Months Ended June 30, 2018
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA
|
|
$
|
5,643
|
|
|
|
$
|
(758
|
)
|
|
|
$
|
4,885
|
|
|
|
|
|
|
|
|
|
|
Intersegment
|
|
|
|
|
||||||||||
|
|
Services
|
|
True Health
|
Eliminations
|
Consolidated
|
|
||||||||||||||
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Six Months Ended June 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
|
$
|
5,297
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
5,297
|
|
|
|
Platform and operations
|
|
297,949
|
|
|
|
—
|
|
|
|
(6,135
|
)
|
|
|
291,814
|
|
|
|
||||
Services revenue
|
|
303,246
|
|
|
|
—
|
|
|
|
(6,135
|
)
|
|
|
297,111
|
|
|
|
||||
True Health:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Premiums
|
|
—
|
|
|
|
93,140
|
|
|
|
(536
|
)
|
|
|
92,604
|
|
|
|
||||
Total revenue
|
|
$
|
303,246
|
|
|
|
$
|
93,140
|
|
|
|
$
|
(6,671
|
)
|
|
|
$
|
389,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Six Months Ended June 30, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Transformation services
|
|
$
|
14,720
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
14,720
|
|
|
|
Platform and operations
|
|
230,576
|
|
|
|
—
|
|
|
|
(7,412
|
)
|
|
|
223,164
|
|
|
|
||||
Services revenue
|
|
245,296
|
|
|
|
—
|
|
|
|
(7,412
|
)
|
|
|
237,884
|
|
|
|
||||
True Health:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Premiums
|
|
—
|
|
|
|
46,524
|
|
|
|
(396
|
)
|
|
|
46,128
|
|
|
|
||||
Total revenue
|
|
$
|
245,296
|
|
|
|
$
|
46,524
|
|
|
|
$
|
(7,808
|
)
|
|
|
$
|
284,012
|
|
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
||||||
|
|
Services
|
|
True Health
|
Total
|
|
||||||||||
Six Months Ended June 30, 2019
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA
|
|
$
|
(24,296
|
)
|
|
|
$
|
1,844
|
|
|
|
$
|
(22,452
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Six Months Ended June 30, 2018
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA
|
|
$
|
12,609
|
|
|
|
$
|
189
|
|
|
|
$
|
12,798
|
|
|
|
|
|
For the Three
|
|
For the Six
|
||||||||||||
|
|
Months Ended
|
|
Months Ended
|
||||||||||||
|
|
June 30,
|
|
June 30,
|
||||||||||||
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Net Income (Loss) Attributable to
|
|
|
|
|
|
|
|
|
||||||||
Evolent Health, Inc.
|
|
$
|
(31,615
|
)
|
|
$
|
(9,916
|
)
|
|
$
|
(78,354
|
)
|
|
$
|
(23,542
|
)
|
Less:
|
|
|
|
|
|
|
|
|
||||||||
Interest income
|
|
842
|
|
|
878
|
|
|
1,902
|
|
|
1,950
|
|
||||
Interest expense
|
|
(3,620
|
)
|
|
(855
|
)
|
|
(7,182
|
)
|
|
(1,708
|
)
|
||||
(Provision) benefit for income taxes
|
|
(1,398
|
)
|
|
109
|
|
|
(902
|
)
|
|
106
|
|
||||
Depreciation and amortization expenses
|
|
(15,292
|
)
|
|
(10,034
|
)
|
|
(29,558
|
)
|
|
(19,530
|
)
|
||||
Income (loss) from equity method investees
|
|
(1,904
|
)
|
|
(1,275
|
)
|
|
(2,328
|
)
|
|
(1,406
|
)
|
||||
Gain (loss) on disposal of assets
|
|
9,600
|
|
|
—
|
|
|
9,600
|
|
|
—
|
|
||||
Change in fair value of contingent consideration
|
|
|
|
|
|
|
|
|
||||||||
and indemnification asset
|
|
(100
|
)
|
|
1,604
|
|
|
(200
|
)
|
|
1,504
|
|
||||
Other income (expense), net
|
|
(587
|
)
|
|
78
|
|
|
(160
|
)
|
|
60
|
|
||||
Net (income) loss attributable to
|
|
|
|
|
|
|
|
|
||||||||
non-controlling interests
|
|
285
|
|
|
115
|
|
|
2,195
|
|
|
554
|
|
||||
ASC 606 transition adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,498
|
)
|
||||
Purchase accounting adjustments
|
|
(165
|
)
|
|
(216
|
)
|
|
(761
|
)
|
|
(433
|
)
|
||||
Stock-based compensation expense
|
|
(4,750
|
)
|
|
(4,718
|
)
|
|
(9,287
|
)
|
|
(8,513
|
)
|
||||
Severance costs
|
|
(3,881
|
)
|
|
105
|
|
|
(14,483
|
)
|
|
(1,489
|
)
|
||||
Amortization of contract cost assets
|
|
(776
|
)
|
|
(578
|
)
|
|
(1,552
|
)
|
|
(1,139
|
)
|
||||
Transaction costs
|
|
(2,195
|
)
|
|
(14
|
)
|
|
(3,186
|
)
|
|
(1,798
|
)
|
||||
Adjusted EBITDA
|
|
$
|
(7,674
|
)
|
|
$
|
4,885
|
|
|
$
|
(22,452
|
)
|
|
$
|
12,798
|
|
|
|
For the Six Months Ended June 30,
|
|
|||||||||||||||||||||||||||
|
|
2019
|
|
|
2018
|
|
||||||||||||||||||||||||
|
|
Services (1)
|
True Health
|
Consolidated
|
|
Services (1)
|
True Health
|
Consolidated
|
||||||||||||||||||||||
Beginning balance
|
|
$
|
17,715
|
|
|
|
$
|
9,880
|
|
|
|
$
|
27,595
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
Incurred costs related to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current year
|
|
88,261
|
|
|
|
73,359
|
|
|
|
161,620
|
|
|
|
—
|
|
|
|
35,177
|
|
|
|
35,177
|
|
|
||||||
Prior years
|
|
244
|
|
|
|
483
|
|
|
|
727
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
||||||
Total incurred
|
|
88,505
|
|
|
|
73,842
|
|
|
|
162,347
|
|
|
|
—
|
|
|
|
35,177
|
|
|
|
35,177
|
|
|
||||||
Paid costs related to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current year
|
|
73,781
|
|
|
|
26,473
|
|
|
|
100,254
|
|
|
|
—
|
|
|
|
25,711
|
|
|
|
25,711
|
|
|
||||||
Prior years
|
|
7,837
|
|
|
|
8,003
|
|
|
|
15,840
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
||||||
Total paid
|
|
81,618
|
|
|
|
34,476
|
|
|
|
116,094
|
|
|
|
—
|
|
|
|
25,711
|
|
|
|
25,711
|
|
|
||||||
Other adjustments (2)
|
|
(187
|
)
|
|
|
(40,609
|
)
|
|
|
(40,796
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
||||||
Change during the year
|
|
6,700
|
|
|
|
(1,243
|
)
|
|
|
5,457
|
|
|
|
—
|
|
|
|
9,466
|
|
|
|
9,466
|
|
|
||||||
Ending balance
|
|
$
|
24,415
|
|
|
|
$
|
8,637
|
|
|
|
$
|
33,052
|
|
|
|
$
|
—
|
|
|
|
$
|
9,466
|
|
|
|
$
|
9,466
|
|
|
|
As of June 30, 2019
|
||||||||||||||
|
|
|
Gross
|
|
Gross
|
|
|
||||||||
|
Amortized
|
|
Unrealized
|
|
Unrealized
|
|
Fair
|
||||||||
|
Cost
|
|
Gains
|
|
Losses
|
|
Value
|
||||||||
U.S. Treasury bills
|
$
|
12,248
|
|
|
$
|
329
|
|
|
$
|
—
|
|
|
$
|
12,577
|
|
Corporate bonds
|
1,704
|
|
|
70
|
|
|
—
|
|
|
1,774
|
|
||||
Other CMOs
|
2,584
|
|
|
45
|
|
|
—
|
|
|
2,629
|
|
||||
Yankees
|
596
|
|
|
34
|
|
|
—
|
|
|
630
|
|
||||
Total investments
|
$
|
17,132
|
|
|
$
|
478
|
|
|
$
|
—
|
|
|
$
|
17,610
|
|
|
As of December 31, 2018
|
||||||||||||||
|
|
|
Gross
|
|
Gross
|
|
|
||||||||
|
Amortized
|
|
Unrealized
|
|
Unrealized
|
|
Fair
|
||||||||
|
Cost
|
|
Gains
|
|
Losses
|
|
Value
|
||||||||
U.S. Treasury bills
|
$
|
7,982
|
|
|
$
|
120
|
|
|
$
|
—
|
|
|
$
|
8,102
|
|
Corporate bonds
|
887
|
|
|
17
|
|
|
—
|
|
|
904
|
|
||||
Other CMOs
|
545
|
|
|
6
|
|
|
—
|
|
|
551
|
|
||||
Yankees
|
596
|
|
|
11
|
|
|
—
|
|
|
607
|
|
||||
Total investments
|
$
|
10,010
|
|
|
$
|
154
|
|
|
$
|
—
|
|
|
$
|
10,164
|
|
|
As of June 30, 2019
|
|
As of December 31, 2018
|
||||||||||||
|
Amortized
|
|
Fair
|
|
Amortized
|
|
Fair
|
||||||||
|
Cost
|
|
Value
|
|
Cost
|
|
Value
|
||||||||
Due in one year or less
|
$
|
4,048
|
|
|
$
|
4,057
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Due after one year through five years
|
13,084
|
|
|
13,553
|
|
|
9,666
|
|
|
9,813
|
|
||||
Due after five years through ten years
|
—
|
|
|
—
|
|
|
344
|
|
|
351
|
|
||||
Total
|
$
|
17,132
|
|
|
$
|
17,610
|
|
|
$
|
10,010
|
|
|
$
|
10,164
|
|
|
For the Six
|
||||||
|
Months Ended
|
||||||
|
June 30,
|
||||||
|
2019
|
|
2018
|
||||
Supplemental disclosure of cash flow information
|
|
|
|
||||
Operating cash flows from operating leases
|
$
|
6,542
|
|
|
$
|
—
|
|
Leased assets obtained in exchange for new operating lease liabilities
|
30,181
|
|
|
—
|
|
||
|
|
|
|
||||
Non-cash investing and financing activities
|
|
|
|
||||
Accrued property and equipment purchases
|
$
|
166
|
|
|
$
|
875
|
|
Class A common stock issued for payment of Passport earn-out
|
800
|
|
|
—
|
|
||
Increase to goodwill from measurement period adjustments
|
|
|
|
||||
related to business combinations
|
596
|
|
|
128
|
|
||
Consideration for asset acquisitions or business combinations
|
16,000
|
|
|
500
|
|
||
Settlement of escrow related to asset acquisition
|
—
|
|
|
2,519
|
|
||
Settlement of indemnification asset
|
—
|
|
|
1,004
|
|
||
Effects of Class B Exchanges
|
|
|
|
||||
Decrease in non-controlling interests as a result of Class B Exchanges
|
33,946
|
|
|
25,334
|
|
||
Decrease in deferred tax liability as a result of securities offerings
|
—
|
|
|
908
|
|
|
For the Three
|
|
|
|
For the Six
|
|
|
|
|
||||||||||||||||||
|
Months Ended
|
|
Change Over
|
|
Months Ended
|
|
Change Over
|
||||||||||||||||||||
|
June 30,
|
|
Prior Period
|
|
June 30,
|
|
Prior Period
|
||||||||||||||||||||
(in thousands)
|
2019
|
|
2018
|
|
$
|
|
%
|
|
2019
|
|
2018
|
|
$
|
|
%
|
||||||||||||
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Transformation services
|
$
|
1,944
|
|
|
$
|
8,215
|
|
|
$
|
(6,271
|
)
|
|
(76.3)%
|
|
$
|
5,297
|
|
|
$
|
14,720
|
|
|
$
|
(9,423
|
)
|
|
(64.0)%
|
Platform and operations services
|
144,522
|
|
|
113,346
|
|
|
31,176
|
|
|
27.5%
|
|
291,814
|
|
|
223,164
|
|
|
68,650
|
|
|
30.8%
|
||||||
Total Services
|
146,466
|
|
|
121,561
|
|
|
24,905
|
|
|
20.5%
|
|
297,111
|
|
|
237,884
|
|
|
59,227
|
|
|
24.9%
|
||||||
True Health:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Premiums
|
45,493
|
|
|
22,737
|
|
|
22,756
|
|
|
100.1%
|
|
92,604
|
|
|
46,128
|
|
|
46,476
|
|
|
100.8%
|
||||||
Total revenue
|
191,959
|
|
|
144,298
|
|
|
47,661
|
|
|
33.0%
|
|
389,715
|
|
|
284,012
|
|
|
105,703
|
|
|
37.2%
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cost of revenue (exclusive of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
expenses presented separately below)
|
108,383
|
|
|
69,003
|
|
|
39,380
|
|
|
57.1%
|
|
225,824
|
|
|
140,978
|
|
|
84,846
|
|
|
60.2%
|
||||||
Claims expenses
|
36,085
|
|
|
18,428
|
|
|
17,657
|
|
|
95.8%
|
|
73,842
|
|
|
35,177
|
|
|
38,665
|
|
|
109.9%
|
||||||
Selling, general and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
administrative expenses
|
66,932
|
|
|
57,403
|
|
|
9,529
|
|
|
16.6%
|
|
141,770
|
|
|
112,929
|
|
|
28,841
|
|
|
25.5%
|
||||||
Depreciation and amortization expenses
|
15,292
|
|
|
10,034
|
|
|
5,258
|
|
|
52.4%
|
|
29,558
|
|
|
19,530
|
|
|
10,028
|
|
|
51.3%
|
||||||
(Gain) loss on disposal of assets
|
(9,600
|
)
|
|
—
|
|
|
(9,600
|
)
|
|
—%
|
|
(9,600
|
)
|
|
—
|
|
|
(9,600
|
)
|
|
—%
|
||||||
Change in fair value of contingent
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
consideration and indemnification asset
|
100
|
|
|
(1,604
|
)
|
|
1,704
|
|
|
(106.2)%
|
|
200
|
|
|
(1,504
|
)
|
|
1,704
|
|
|
(113.3)%
|
||||||
Total operating expenses
|
217,192
|
|
153,264
|
|
|
63,928
|
|
|
41.7%
|
|
461,594
|
|
|
307,110
|
|
|
154,484
|
|
|
50.3%
|
|||||||
Operating income (loss)
|
$
|
(25,233
|
)
|
|
$
|
(8,966
|
)
|
|
$
|
(16,267
|
)
|
|
(181.4)%
|
|
$
|
(71,879
|
)
|
|
$
|
(23,098
|
)
|
|
$
|
(48,781
|
)
|
|
(211.2)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Transformation services revenue as
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
a % of total revenue
|
1.0
|
%
|
|
5.7
|
%
|
|
|
|
|
|
1.4
|
%
|
|
5.2
|
%
|
|
|
|
|
||||||||
Platform and operations services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
revenue as a % of total revenue
|
75.3
|
%
|
|
78.5
|
%
|
|
|
|
|
|
74.9
|
%
|
|
78.6
|
%
|
|
|
|
|
||||||||
Premiums as a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
% of total revenue
|
23.7
|
%
|
|
15.8
|
%
|
|
|
|
|
|
23.8
|
%
|
|
16.2
|
%
|
|
|
|
|
||||||||
Cost of revenue as a %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
of Services revenue
|
74.0
|
%
|
|
56.8
|
%
|
|
|
|
|
|
76.0
|
%
|
|
59.3
|
%
|
|
|
|
|
||||||||
Claims expenses as a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
% of premiums
|
79.3
|
%
|
|
81.0
|
%
|
|
|
|
|
|
79.7
|
%
|
|
76.3
|
%
|
|
|
|
|
||||||||
Selling, general and administrative
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
expenses as a % of total revenue
|
34.9
|
%
|
|
39.8
|
%
|
|
|
|
|
|
36.4
|
%
|
|
39.8
|
%
|
|
|
|
|
|
For the Six
|
||||||
|
Months Ended
|
||||||
|
June 30,
|
||||||
|
2019
|
|
2018
|
||||
Net cash and restricted cash provided by (used in) operating activities
|
$
|
(39,242
|
)
|
|
$
|
(18,004
|
)
|
Net cash and restricted cash provided by (used in) investing activities
|
(90,816
|
)
|
|
(19,376
|
)
|
||
Net cash and restricted cash provided by (used in) financing activities
|
(121,071
|
)
|
|
(3,665
|
)
|
|
2019
|
|
2020-2021
|
|
2022-2023
|
|
Thereafter
|
|
Total
|
||||||||||
Operating leases for facilities
|
$
|
4,450
|
|
|
$
|
22,240
|
|
|
$
|
20,073
|
|
|
$
|
66,852
|
|
|
$
|
113,615
|
|
Contingent loan commitments
|
11,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11,000
|
|
|||||
Purchase obligations related to vendor contracts
|
4,199
|
|
|
2,157
|
|
|
—
|
|
|
—
|
|
|
6,356
|
|
|||||
Convertible debt interest payments
|
2,539
|
|
|
10,187
|
|
|
5,165
|
|
|
5,101
|
|
|
22,992
|
|
|||||
Convertible debt principal repayment
|
—
|
|
|
125,000
|
|
|
—
|
|
|
172,500
|
|
|
297,500
|
|
|||||
Total
|
$
|
22,188
|
|
|
$
|
159,584
|
|
|
$
|
25,238
|
|
|
$
|
244,453
|
|
|
$
|
451,463
|
|
•
|
Increase our ownership in our consolidated operating subsidiary, Evolent Health LLC. See “Part I - Item 1. Financial Statements - Note 15” in this Form 10-Q for additional information;
|
•
|
Increase the number of outstanding shares of our Class A common stock. See “Part I - Item 1. Financial Statements - Note 11” in this Form 10-Q for information relating to potentially dilutive securities and the impact on our historical earnings per share; and
|
•
|
Increase our tax basis in our share of Evolent Health LLC’s tangible and intangible assets and possibly subject us to payments under the TRA agreement. See “Part I - Item 1. Financial Statements - Note 13” in this Form 10-Q for further information on tax matters related to the exchange of Class B common shares.
|
•
|
assimilation of the acquired businesses, which may divert significant management attention and financial resources from our other operations and could disrupt our ongoing business;
|
•
|
challenges related to the integration and operation of businesses that operate in new geographic areas and new markets or lines of business;
|
•
|
failure to realize the potential cost savings or other financial benefits or the strategic benefits of the acquisitions, including failure to consummate any proposed or contemplated transaction; and
|
•
|
liabilities, including acquired litigation, and expenses from the acquired businesses for contractual disputes with customers and other third parties, infringement of intellectual property rights, data privacy violations or other claims and failure to obtain indemnification for such liabilities or claims, and distraction of our personnel in connection with any related proceedings.
|
EVOLENT HEALTH, INC.
|
|
|
Registrant
|
|
|
|
|
|
By:
|
/s/ John Johnson
|
|
Name:
|
John Johnson
|
|
Title:
|
Chief Financial Officer
|
|
|
|
|
By:
|
/s/ Lydia Stone
|
|
Name:
|
Lydia Stone
|
|
Title:
|
Chief Accounting Officer and Controller
|
Article I. PURCHASE OF ASSETS
|
2
|
|
|
Section 1.1
|
Acquired Assets
|
2
|
|
Section 1.2
|
Excluded Assets
|
3
|
|
Section 1.3
|
Assumed Liabilities
|
4
|
|
Section 1.4
|
Excluded Liabilities
|
4
|
|
Section 1.5
|
Unassisnable Contracts
|
4
|
|
Section 1.6
|
Purchase Price
|
5
|
|
Section 1.7
|
Allocation
|
5
|
|
Article II. REPRESENTATIONS AND WARRANTIES OF SELLER
|
5
|
|
|
Section 2.1
|
Organization and Good Standing
|
6
|
|
Section 2.2
|
Authority; No Conflict
|
6
|
|
Section 2.3
|
Financial Statements
|
6
|
|
Section 2.4
|
Subsidiaries
|
6
|
|
Section 2.5
|
Assets
|
7
|
|
Section 2.6
|
Taxes
|
7
|
|
Section 2.7
|
Employees and Employee Benefits.
|
7
|
|
Section 2.8
|
Licenses, Permits and Approvals
|
9
|
|
Section 2.9
|
Legal Proceedings, Orders.
|
9
|
|
Section 2.10
|
Compliance with Legal Requirements; Governmental Authorizations.
|
9
|
|
Section 2.11
|
Insurance
|
10
|
|
Section 2.12
|
Contracts; No Defaults
|
10
|
|
Section 2.13
|
Intellectual Property.
|
12
|
|
Section 2.14
|
No Undisclosed Liabilities
|
13
|
|
Section 2.15
|
Absence of Certain Changes and Events
|
13
|
|
Section 2.16
|
Brokers or Finders
|
13
|
|
Section 2.17
|
Real Property
|
13
|
|
Section 2.18
|
Disclosure
|
14
|
|
Section 2.19
|
Material Vendors and Top Providers.
|
14
|
|
Section 2.20
|
Securities Laws Matters
|
15
|
|
Article III. [RESERVED]
|
15
|
|
|
Article IV. REPRESENTATIONS AND WARRANTIES OF BUYER AND EVOLENT
|
15
|
|
|
Section 4.1
|
Organization and Good Standing
|
15
|
|
Section 4.2
|
Authority, No Conflict
|
15
|
|
Section 4.3
|
Employee Benefit Plans
|
16
|
|
Section 4.4
|
Brokers or Finders
|
17
|
|
Section 4.5
|
Consummation of Transactions
|
17
|
|
Section 4.6
|
No Outside Reliance
|
17
|
|
Section 4.7
|
Disclosure
|
18
|
|
Article V. CERTAIN COVENANTS
|
18
|
|
|
Section 5.1
|
Certain Actions to Close Transactions
|
18
|
|
Section 5.2
|
Buyer’s Covenant to Qualify; Seller’s Covenant to Assist.
|
18
|
|
Section 5.3
|
Further Assurances
|
19
|
|
Section 5.4
|
Post-Closing Cooperation
|
19
|
|
Section 5.5
|
Items to Proper Party
|
19
|
|
Section 5.6
|
Access and Information; Confidentiality.
|
19
|
|
Section 5.7
|
Exclusivity
|
21
|
|
Section 5.8
|
Conduct of Business Prior to the Closing.
|
21
|
|
Section 5.9
|
Employees
|
23
|
|
Section 5.10
|
Public Announcements
|
24
|
|
Section 5.11
|
Post-Closing Access; Preservation of Records
|
24
|
|
Section 5.12
|
Notification and Effect of Certain Matters
|
25
|
|
Section 5.13
|
Assistance with SEC Filings
|
26
|
|
Section 5.14
|
Branding
|
26
|
|
Section 5.15
|
Capital Commitment
|
26
|
|
Section 5.16
|
West Louisville Development. .
|
26
|
|
Section 5.17
|
Tail Insurance.
|
27
|
|
Article VI. CLOSING AND CLOSING DELIVERIES
|
27
|
|
|
Section 6.1
|
Closing
|
27
|
|
Section 6.2
|
Closing Deliveries by Seller
|
27
|
|
Section 6.3
|
Closing Deliveries by Buyer and Evolent
|
28
|
|
Article VII. CONDITIONS TO OBLIGATIONS TO CLOSE
|
28
|
|
|
Section 7.1
|
Conditions to Obligation of Buyer and Evolent to Close
|
28
|
|
Section 7.2
|
Conditions to Obligation of Seller to Close
|
29
|
|
Article VIII. INDEMNIFICATION
|
30
|
|
|
Section 10.1
|
Expenses
|
35
|
|
Section 10.2
|
Assignment; No Third Party Beneficiaries
|
35
|
|
Section 10.3
|
Notices
|
35
|
|
Section 10.4
|
Waiver
|
36
|
|
Section 10.5
|
Entire Agreement; Modification
|
36
|
|
Section 10.6
|
Severability
|
36
|
|
Section 10.7
|
Headings; Construction
|
36
|
|
Section 10.8
|
Governing Law
|
36
|
|
Section 10.9
|
Execution of Agreement; Counterparts
|
37
|
|
Section 10.10
|
Consent to Assignment
|
37
|
|
Section 10.11
|
Enforcement of Agreement
|
37
|
|
Section 10.12
|
Disclosure Schedules
|
37
|
|
Section 10.13
|
Guarantees
|
37
|
|
A.
|
Seller operates a business that administers and delivers Medicaid managed care benefits in the Commonwealth of Kentucky through contracts with the Kentucky Cabinet for Health and Family Services (“CHFS”), and a business that administers and delivers managed care benefits in the Commonwealth of Kentucky through a Dual Eligible Special Needs Plans contract with CMS (collectively, the “Business”).
|
B.
|
As a result of, amongst other things, Seller’s need for additional capital and Seller’s desire to maintain the Business and not wind it down, Seller has determined that it is in the best interest of its Sponsors, its members and the Commonwealth of Kentucky, and in the furtherance of its overall charitable purposes and the proper administration of its charitable assets, to consider strategic alternatives for the ownership and operation of the Business and the ownership of the Acquired Assets (as defined herein), including the sale of the Acquired Assets to a qualified owner and operator that will continue the Business’ operations primarily in Louisville, Kentucky.
|
C.
|
Evolent, through its subsidiaries, provides administrative and management services for the Business pursuant that certain Services Agreement, dated as of December 16, 2015, between Evolent Health LLC and Passport, as amended from time to time (as amended, the “Services Agreement”).
|
D.
|
Each Party desires that Seller sell, convey, transfer and assign to Buyer, and that Buyer purchase, acquire and accept from Seller substantially all of the assets of Seller related to the Business, and that Buyer assume certain liabilities of Seller related thereto, all upon and subject to the terms herein.
|
E.
|
The Parties also believe that a transaction in which the Buyer acquires the Acquired Assets will allow the Buyer, working with the Sponsors to: (i) further the clinical integration of healthcare delivery platforms in the communities served by the Sponsors; (ii) allow for an increase in the efficiency of the delivery of healthcare services in the Commonwealth of Kentucky; and (iii) sustain and enhance, in particular, the mission of the University of Louisville to further research in medicine, dentistry, nursing and public health matters for the greater good.
|
1.
|
on behalf of Seller, to the Persons owed Transaction Expenses as directed by Seller and pursuant to releases and invoices, in each case, in a form and substance reasonably satisfactory to Buyer; and
|
2.
|
an aggregate amount equal to (A) the Cash Purchase Price minus (b) the Transaction Expenses paid by Buyer on behalf of Seller pursuant to Section 1.6(b)(ii), which amount shall be deposited into one (1) or more accounts as designated by Seller by written notice to Buyer not less than three (3) Business Days prior to the Closing Date; and
|
Defined Term
|
Section
|
Agreement
|
First Paragraph
|
Acquired Assets
|
Section 1.1
|
Acquisition Proposal
|
Section 5.7
|
Assumed Liabilities
|
Section 1.3
|
Assumed Contracts
|
Section 1.1
|
Balance Sheet Date
|
Section 2.3
|
Basket
|
Section 8.5(a)
|
Bill of Sale
|
Section 6.2(a)
|
Business
|
Recitals
|
Buyer
|
First Paragraph
|
Buyer Benefit Plans
|
Section 4.3(a)
|
Buyer Common Stock
|
Section 1.6(a)
|
Buyer Fundamental Representations
|
Section 8.6(c)
|
Buyer Indemnified Persons
|
Section 8.2
|
Cap
|
Section 8.5(b)
|
CHFS
|
Recitals
|
Closing
|
Section 6.1
|
Closing Date
|
Section 6.1
|
COBRA
|
Section 2.7(g)
|
Damages
|
Section 8.2
|
DOJ
|
Section 5.2(b)
|
Effective Time
|
Section 6.1
|
Equity Consideration
|
Section 1.6(a)
|
Evolent
|
First Paragraph
|
Excluded Assets
|
Section 1.2
|
Excluded Liabilities
|
Section 1.4
|
FTC
|
Section 5.2(b)
|
Improvements
|
Section 2.17(d)
|
Indemnified Person
|
Section 8.8(a)
|
Indemnifying Person
|
Section 8.8(a)
|
Material Contract
|
Section 2.12(a)
|
Material Vendors
|
Section 2.19(a)
|
Materiality Qualifiers
|
Section 8.12
|
Medicaid RFP
|
Section 5.8(c)
|
Owned Real Property
|
Section 2.17(a)
|
Party
|
First Paragraph
|
Passport
|
First Paragraph
|
Defined Term
|
Section
|
PHS I
|
First Paragraph
|
Provider Contract
|
Section 1.1
|
Purchase Price
|
Section 1.6(a)
|
Real Property
|
Section 2.17(a)
|
Schedule Supplement
|
Section 5.12(a)
|
Seller
|
First Paragraph
|
Seller Benefit Plans
Seller Employees
|
Section 2.7(b)
Section 2.7(a)
|
Seller Financial Statements
|
Section 2.3
|
Seller Fundamental Representations
|
Section 8.5(c)
|
Seller Indemnified Persons
|
Section 8.4
|
Seller Intellectual Property
|
Section 2.13(a)
|
Seller Licenses and Permits
|
Section 2.8
|
Seller Real Property Leases
|
Section 2.17(a)
|
Services Agreement
|
Recitals
|
Shareholders Agreement
|
Section 6.2(f)
|
Trademark Assignment Agreement
|
Section 6.2(i)
|
Transferred Employees
|
Section 5.9
|
Third-Party Claim
|
Section 8.8(a)
|
Top Provider
|
Section 2.19
|
WARN Act
|
Section 5.9(c)
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Evolent Health, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated:
|
August 9, 2019
|
/s/ Frank Williams
|
|
|
|
Name: Frank Williams
|
|
|
|
Title: Chief Executive Officer
|
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Evolent Health, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated:
|
August 9, 2019
|
/s/ John Johnson
|
|
|
|
Name: John Johnson
|
|
|
|
Title: Chief Financial Officer
|
|
1.
|
The Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2019 (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated:
|
August 9, 2019
|
/s/ Frank Williams
|
|
|
|
Name: Frank Williams
|
|
|
|
Title: Chief Executive Officer
|
|
1.
|
The Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2019 (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated:
|
August 9, 2019
|
/s/ John Johnson
|
|
|
|
Name: John Johnson
|
|
|
|
Title: Chief Financial Officer
|
|